Beijing Biostar Pharmaceuticals Company Description

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China.

The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant intensive, first line gastric cancer, platinum-resistant ovarian cancer, and soft tissue sarcoma indications.

It is also involved in the development of Utidelone antibody drug conjugate in preclinical studies; and BG22, BG18, and BG44 products for solid tumor indications in preclinical studies.

Beijing Biostar Pharmaceuticals Co., Ltd. was incorporated in 2002 and is headquartered in Beijing, China.

Beijing Biostar Pharmaceuticals Co., Ltd.

Country	China
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	134
CEO	Rongguo Qiu

Contact Details

Address: Building 3, Tower B, Yicheng Fortune Center Beijing, 100176 China
Phone	86 10 6786 4938
Website	biostar-pharm.com

Stock Details

Ticker Symbol	2563
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100006NB3
SIC Code	2836

Key Executives

Name	Position
Dr. Rongguo Qiu	Co- Founder, Vice-Chairperson, Chief Executive Officer and GM
Dr. Li Tang	Co-Founder, Chairperson, Chief Scientific Officer and Chief Marketing Officer
Cheng Zhang	Deputy GM, Vice President and Executive Director
Dr. Jin Guan	Deputy GM and Executive Director
Fei Peng	Financial Director
Xin Chen	Operation Director
Kailin Liu	Investment Director and Joint Company Secretary
Wei He	Head of administration
Aoshuang Huang	Human Resource Director
Mingwu Yang	Head of equipment power